Intellia Therapeutics Inc (NTLA) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Intellia Therapeutics Inc $2.17, price $12.33, upside -82.4%, quality 30 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Intellia Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $6.28 – $176.78 · fair‑value band $1.43 – $2.70 · the $12.33 price screens above the $2.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Intellia Therapeutics in your weekly email
Every Wednesday you see whether Intellia Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing.
Show more
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Stock analysis
Intellia Therapeutics Inc (NTLA) currently trades at $12.33, while our model-based Fair Value estimate is $2.17, implying the stock looks roughly 468.8% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $1.43 (bear) to $2.70 (bull), the price of $12.33 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Intellia Therapeutics Inc reported revenue of $67.7M in FY2025 versus $33.1M in FY2021, a compound +19.6%/yr. Reported net income was −$413M in FY2025.
Key figures
Market cap $1.6B · P/S ratio 33.1 · EPS (TTM) $−3.52 · Return on equity −56.3% · Return on assets (EBIT) −37.5% · Operating margin −668% · Revenue (TTM) $66.1M · Revenue growth (YoY) −9.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 56% below its 52-week high and 53% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −82%, NTLA screens richer than that median.
Fair Value models
Bear $1.43Fair Value $2.17Bull $2.70
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.9/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+16.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
Start year 2020 (pandemic). Over 10 years: +27.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−235.5% (2020) → −651.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Intellia Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−83% · Bottom 25%
Profitability
Return on assets−30% · Bottom 25%
Growth and dividend
Revenue growth−46% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B2.52× · Pricier than median
P/S (TTM)28.47× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Intellia Therapeutics Inc (NTLA) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $2.17 versus a price of $12.33, about −82% upside (overvalued).
What is the fair value of NTLA?
Our model-based fair value for Intellia Therapeutics Inc is $2.17 (as of Sep 24, 2026), built from audited fundamentals. The current price: $12.33.
What is the quality score of NTLA?
Intellia Therapeutics Inc has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Intellia Therapeutics Inc (NTLA)?
Our model-based price target is the fair value of $2.17 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $1.43, optimistic scenario $2.70. It is a calculation from audited fundamentals, not an analyst target.
What is the Intellia Therapeutics Inc stock forecast for 2026?
Our models put fair value at $2.17, about −82% upside versus a price of $12.33 (overvalued). Cautious scenario $1.43, optimistic scenario $2.70. The calculation is refreshed regularly with new filings.
What is the revenue of Intellia Therapeutics Inc (NTLA)?
Intellia Therapeutics Inc reported trailing-twelve-month revenue of about $66.1M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Intellia Therapeutics Inc (NTLA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Intellia Therapeutics Inc it is $2.17 per share (as of Sep 24, 2026), against a price of $12.33. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Intellia Therapeutics Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, NTLA trades above its calculated fair value: price $12.33, fair value $2.17, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NTLA?
No. The price is what the market pays today ($12.33); the fair value is what the company's own numbers justify ($2.17). For Intellia Therapeutics Inc the two are $10.16 per share apart. That gap is exactly why we show both numbers side by side.
How much is Intellia Therapeutics Inc worth?
The market values Intellia Therapeutics Inc at about $1.6B (market capitalisation, as of Sep 24, 2026). Per share that is $12.33; our models calculate a fair value of $2.17 per share.
What do the bullish and bearish scenarios say about NTLA?
Our models span a range for Intellia Therapeutics Inc: cautious scenario $1.43, base $2.17, optimistic $2.70 per share (as of Sep 24, 2026, price $12.33). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Intellia Therapeutics Inc (NTLA)?
Balance-sheet figures for Intellia Therapeutics Inc (as of Sep 24, 2026): return on equity −55.4%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is NTLA from its 52-week high?
Intellia Therapeutics Inc trades at $12.33, about 56% below its 52-week high of $27.98 and 53% above the low of $8.04 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $2.17 is for.
Which stocks are comparable to Intellia Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Intellia Therapeutics Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $12.33, calculated fair value $2.17 (−82%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NTLA calculated?
We run Intellia Therapeutics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.17, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Intellia Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Intellia Therapeutics Inc (NTLA)?
The closing price on Sep 23, 2026 was $12.33. Our model-based fair value is $2.17, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Intellia Therapeutics Inc right now?
The price sits above even our optimistic bull case ($2.70). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.43 to $2.70) leaves room in how you read the outcome.
Key figures of Intellia Therapeutics Inc
How large is the market capitalisation of Intellia Therapeutics Inc (NTLA)?
The market capitalisation of Intellia Therapeutics Inc is $1.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Intellia Therapeutics Inc (NTLA)?
The price-to-sales ratio of Intellia Therapeutics Inc is 33.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Intellia Therapeutics Inc (NTLA)?
Earnings per share at Intellia Therapeutics Inc are $−3.52. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Intellia Therapeutics Inc (NTLA)?
The return on equity (ROE) of Intellia Therapeutics Inc is −56.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Intellia Therapeutics Inc (NTLA)?
On an EBIT basis the return on assets of Intellia Therapeutics Inc is −37.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Intellia Therapeutics Inc (NTLA)?
The operating margin of Intellia Therapeutics Inc is −668% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Intellia Therapeutics Inc (NTLA)?
Revenue at Intellia Therapeutics Inc is growing −9.5% versus a year earlier (3y avg +9.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Intellia Therapeutics Inc (NTLA) generate?
The free cash flow of Intellia Therapeutics Inc is −$355M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Intellia Therapeutics Inc (NTLA) hold?
Intellia Therapeutics Inc holds more cash than debt, $62.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Intellia Therapeutics Inc in the live analysis
One click puts Intellia Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026